Use of dual-point fluorodeoxyglucose imaging to enhance sensitivity and specificity

Seminars in Nuclear Medicine

Volumn 42, Issue 4, 2012, Pages 267-280

  Schillaci, Orazio ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

BENIGN TUMOR; BRAIN CANCER; BREAST CANCER; CANCER DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; GALLBLADDER CANCER; HEAD AND NECK CANCER; HUMAN; LIVER CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER;

BREAST NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY;

EID: 84861988706     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2012.02.003     Document Type: Review

References (81)

1. Langer A: A systematic review of PET and PET/CT in oncology: A way to personalize cancer treatment in a cost-effective manner? BMC Health Serv Res 2010;10:283
2. Saif MW, Tzannou I, Makrilia N, et al: Role and cost effectiveness of PET/CT in management of patients with cancer. Yale J Biol Med 2010;83:53-65
3. Hillner BE, Siegel BA, Shields AF, et al: Relationship between cancer type and impact of PET and PET/CT on intended management: Findings of the national oncologic PET registry. J Nucl Med 2008;49:1928-1935
4. Rice SL, Roney CA, Daumar P, et al: The next generation of positron emission tomography radiopharmaceuticals in oncology. Semin Nucl Med 2011;41:265-282
5. Pauwels EK, Ribeiro MJ, Stoot JH, et al: FDG accumulation and tumor biology. Nucl Med Biol 1998;25:317-322 (Pubitemid 28219093)
6. Love C, Tomas MB, Tronco GG, et al: FDG-PET of infection and inflammation. Radiographics 2005;25:1357-1368
7. Schillaci O: Hybrid imaging systems in the diagnosis of osteomyelitis and prosthetic joint infection. Q J Nucl Med Mol Imaging 2009;53:95-104
8. Metser U, Even-Sapir E: Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): Accumulated data from four years of experience with PET/CT. Semin Nucl Med 2007;37:206-222 (Pubitemid 46517465)
9. Strauss LG: Fluorine-18 deoxyglucose and false-positive results: A major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996;23:1409-1415
10. Zhuang H, Pourdehnad M, Lambright ES, et al: Dual time point 18F-FDG-PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001;42:1412-1417 (Pubitemid 32852620)
11. Lowe VJ, Duhaylongsod FG, Patz EF, et al: Pulmonary abnormalities and PET data analysis: A retrospective study. Radiology 1997;202:435-439 (Pubitemid 27051739)
12. Nguyen NC, Kaushik A, Wolverson MK, et al: Is there a common SUV threshold in oncological FDG-PET/CT, at least for some common indications? A retrospective study. Acta Oncol 2011;50:670-677
13. Fischman AJ, Alpert NM: FDG-PET in oncology: There's more to it than looking at pictures. J Nucl Med 1993;34:6-11 [editorial] (Pubitemid 23014213)
14. Hamberg LM, Hunter GJ, Alpert NM, et al: The dose uptake ratio as an index of glucose metabolism: Useful parameter or oversimplification? J Nucl Med 1994;35:1308-1312 (Pubitemid 24243143)
15. Yamada S, Kubota K, Kubota R, et al: High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995;36:1301-1306
16. Lodge MA, Lucas JD, Marsden PK, et al: A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999;26:22-30 (Pubitemid 29137735)
17. Boerner AR, Weckesser M, Herzog H, et al: Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 1999;26:226-230 (Pubitemid 29139852)
18. Hustinx R, Smith RJ, Benard F, et al: Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: A potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999;26:1345-1348 (Pubitemid 29467031)
19. Nakamoto Y, Higashi T, Sakahara H, et al: Delayed (18)F-fluoro-2-deoxy-D- glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000;89:2547-2554 (Pubitemid 32011597)
20. Kubota K, Itoh M, Ozaki K, et al: Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 2001;28:696-703
21. Higashi T, Saga T, Nakamoto Y, et al: Relationship between retention index in dual-phase (18)F-FDG-PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 2002;43:173-180 (Pubitemid 34151039)
22. Basu S, Alavi A: Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: Should these be routinely employed in assessing patients with cancer? Eur J Nucl Med Mol Imaging 2007;34:1527-1529 (Pubitemid 47476924)
23. Gallagher BM, Fowler JS, Gutterson NI, et al: Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978;19:1154-1161 (Pubitemid 9059983)
24. Nelson CA, Wang JQ, Leav I, et al: The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models. Nucl Med Biol 1996;23:533-541 (Pubitemid 26233228)
25. Vansteenkiste JF, Stroobants SS: PET scan in lung cancer: Current recommendations and innovation. J Thorac Oncol 2006;1:71-73 (Pubitemid 47164024)
26. Ung YC, Maziak DE, Vanderveen JA, et al: 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: A systematic review. J Natl Cancer Inst 2007;99:1753-1767 (Pubitemid 351767209)
27. Gould MK, Maclean CC, Kuschner WG, et al: Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis. JAMA 2001;21:914-924 (Pubitemid 32171553)
28. Matthies A, Hickeson M, Cuchiara A, et al: Dual time point 18F-FDGPET for the evaluation of pulmonary nodules. J Nucl Med 2002;43:871-875 (Pubitemid 34747808)
29. Alkhawaldeh K, Bural G, Kumar R, et al: Impact of dual-time-point (18)F-FDG-PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 2008;35:246-252
30. Lubberink M, Tolmachev V, Widström C, et al: 110mIn-DTPA-D-Phe1- octreotide for imaging of neuroendocrine tumours with PET. J Nucl Med 2002;43:1391-1397
31. Schillaci O, Travascio L, Bolacchi F, et al: Accuracy of early and delayed FDG-PET-CT and of contrast-enhanced CT in the evaluation of lung nodules: A preliminary study on 30 patients. Radiol Med 2009;114: 890-906
32. MacDonald K, Searle J, Lyburn I: The role of dual time point FDG-PET imaging in the evaluation of solitary pulmonary nodules with an initial standard uptake value less than 2.5. Clin Radiol 2011;66:244-250
33. Xiu Y, Bhutani C, Dhurairaj T, et al: Dual-time point FDG-PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med 2007;32:101-105 (Pubitemid 46148389)
34. Chen CJ, Lee BF, Yao WJ, et al: Dual-phase 18F-FDG-PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. Am J Roentgenol 2008;191:475-479
35. Barger RL Jr, Nandalur KR: Diagnostic performance of dual-time 18F-FDG-PET in the diagnosis of pulmonary nodules: A meta-analysis. Acad Radiol 2012;19:153-158
36. Laffon E, de Clermont H, Begueret H, et al: Assessment of dual-time-point 18F-FDG-PET imaging for pulmonary lesions. Nucl Med Commun 2009;30:455-461
37. Cloran FJ, Banks KP, Song WS, et al: Limitations of dual time point PET in the assessment of lung nodules with low FDG avidity. Lung Cancer 2010;68:66-71
38. Lan XL, Zhang YX, Wu ZJ, et al: The value of dual time point (18)F-FDG-PET imaging for the differentiation between malignant and benign lesions. Clin Radiol 2008;63:756-764
39. Núñez R, Kalapparambath A, Varela J: Improvement in sensitivity with delayed imaging of pulmonary lesions with FDG-PET. Rev Esp Med Nucl 2007;26:196-207 (Pubitemid 47242181)
40. Suga K, Kawakami Y, Hiyama A, et al: Dual-time point 18F-FDGPET/CT scan for differentiation between 18F-FDG avid non-small cell lung cancer and benign lesions. Ann Nucl Med 2009;23:427-435
41. Uesaka D, Demura Y, Ishizaki T, et al: Evaluation of dual-time-point 18F-FDG-PET for staging in patients with lung cancer. J Nucl Med 2008;49:1606-1161
42. Shinya T, Rai K, Okumura Y, et al: Dual-time-point F-18 FDG-PET/CT for evaluation of intrathoracic lymph nodes in patients with non-small cell lung cancer. Clin Nucl Med 2009;34:216-221
43. Kim SJ, Kim YK, Kim IJ, et al: Limited predictive value of dual-time-point F-18 FDG-PET/CT for evaluation of pathologic N1 status in NSCLC patients. Clin Nucl Med 2011;36:434-439
44. Yen RF, Chen KC, Lee JM, et al: 18F-FDG-PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: Is dual time point imaging worth the effort? Eur J Nucl Med Mol Imaging 2008;35:1305-1315
45. Kasai T, Motoori K, Horikoshi T, et al: Dual-time point scanning of integrated FDG-PET/CT for the evaluation of mediastinal and hilar lymph nodes in non-small cell lung cancer diagnosed as operable by contrast-enhanced CT. Eur J Radiol 2010;75:143-146
46. Li M, Wu N, Liu Y, et al: Regional nodal staging with (18)F-FDG-PET- CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging. Eur J Radiol 2011 Apr 19 [Epub ahead of print]. Available at: http://dx.doi.org/10.1016/j.ejrad.2011.03.074
47. Hu M, Han A, Xing L, et al: Value of dual-time-point FDG-PET/CT for mediastinal nodal staging in non-small-cell lung cancer patients with lung comorbidity. Clin Nucl Med 2011;36:429-433
48. Alkhawaldeh K, Biersack HJ, Henke A, et al: Impact of dual-time-point F-18 FDG-PET/CT in the assessment of pleural effusion in patients with non-small-cell lung cancer. Clin Nucl Med 2011;36:423-428
49. Houseni M, Chamroonrat W, Zhuang J, et al: Prognostic implication of dual-phase PET in adenocarcinoma of the lung. J Nucl Med 2010;51:535-542
50. Kim SJ, Kim YK, Kim IJ, et al: Limited prognostic value of dual time point F-18 FDG-PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC). Radiother Oncol 2011;98:105-108
51. Beaulieu S, Kinahan P, Tseng J, et al: SUV varies with time after injection in (18)F-FDG-PET of breast cancer: Characterization and method to adjust for time differences. J Nucl Med 2003;44:1044-1050 (Pubitemid 39663378)
52. Kumar R, Loving VA, Chauhan A, et al: Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG-PET. J Nucl Med 2005;46:1819-1824 (Pubitemid 46196643)
53. Mavi A, Urhan M, Yu JQ, et al: Dual time point 18F-FDG-PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med 2006;47:1440-1446 (Pubitemid 47544929)
54. Caprio MG, Cangiano A, Imbriaco M, et al: Dual-time-point [18F]-FDG-PET/CT in the diagnostic evaluation of suspicious breast lesions. Radiol Med 2010;115:215-224
55. Zytoon AA, Murakami K, El-Kholy MR, et al: Breast cancer with low FDG uptake: Characterization by means of dual-time point FDG-PET/CT. Eur J Radiol 2009;70:530-538
56. Choi WH, Yoo IR, O JH, et al: The value of dual-time-point 18F-FDG-PET/CT for identifying axillary lymph node metastasis in breast cancer patients. Br J Radiol 2011;84:593-599
57. Arena V, Skanjeti A, Casoni R, et al: Dual-phase FDG-PET: Delayed acquisition improves hepatic detectability of pathological uptake. Radiol Med 2008;113:875-886
58. Lee JW, Kim SK, Lee SM, et al: Detection of hepatic metastases using dual-time-point FDG-PET/CT scans in patients with colorectal cancer. Mol Imaging Biol 2011;13:565-572
59. Kitapci MT, Akkaş BE, Gullu I, et al: FDG-PET/CT in the evaluation of epithelioid hemangioendothelioma of the liver: The role of dual-time-point imaging. A case presentation and review of the literature. Ann Nucl Med 2010;24:549-553
60. Nishiyama Y, Yamamoto Y, Fukunaga K, et al: Dual-time-point 18F-FDG-PET for the evaluation of gallbladder carcinoma. J Nucl Med 2006;47:633-638 (Pubitemid 46768464)
61. Shum WY, Hsieh TC, Yeh JJ, et al: Clinical usefulness of dual-time FDG-PET-CT in assessment of esophageal squamous cell carcinoma. Eur J Radiol 2011 Mar 31 [Epub ahead of print]. Available at: http://dx.doi.org/10.1016/j. ejrad.2011.03.018
62. Okano K, Kakinoki K, Akamoto S, et al: 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer. World J Gastroenterol 2011;17:231-235
63. Lyshchik A, Higashi T, Nakamoto Y, et al: Dual-phase 18F-fluoro-2-deoxy- D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 2005;32:389-397 (Pubitemid 40591169)
64. Toriihara A, Yoshida K, Umehara I, et al: Normal variants of bowel FDG uptake in dual-time-point PET/CT imaging. Ann Nucl Med 2011;25:173-178
65. Yen TC, Ng KK, Ma SY, et al: Value of dual-phase 2-fluoro-2-deoxy- dglucose positron emission tomography in cervical cancer. J Clin Oncol 2003;21:3651-3658 (Pubitemid 46594059)
66. Lai CH, Huang KG, See LC, et al: Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography. Cancer 2004;100:544-552 (Pubitemid 38124772)
67. Ma SY, See LC, Lai CH, et al: Delayed 18F-FDG-PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med 2003;44:1775-1783 (Pubitemid 39663309)
68. Kim DW, Jung SA, Kim CG, et al: The efficacy of dual time point F-18 FDG-PET imaging for grading of brain tumors. Clin Nucl Med 2010;35:400-403
69. Prieto E, Martí-Climent JM, Domínguez-Prado I, et al: Voxel-based analysis of dual-time-point 18F-FDG-PET images for brain tumor identification and delineation. J Nucl Med 2011;52:865-872
70. Horky LL, Hsiao EM, Weiss SE, et al: Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. J Neuro Oncol 2011;103:137-146
71. Spence AM, Muzi M, Mankoff DA, et al: 18F-FDG-PET of gliomas at delayed intervals: Improved distinction between tumor and normal gray matter. J Nucl Med 2004;45:1653-1659 (Pubitemid 47618471)
72. Chen YK, Kao CH, Sun SS, et al: Exposing the evil in the dark: The usefulness of delayed-phase FDG-PET scan to enhance the detectability of tiny residual skull base osteosarcoma initially concealed by adjacent high physiological brain activity. Clin Nucl Med 2010;35:630-632
73. Yen TC, Chang YC, Chan SC, et al: Are dual-phase F-18-FDG-PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and locoregional nodes? Eur J Nucl Med Mol Imaging 2005;32:541-548
74. Zhuang H, Hustinx R, Alavi A: Effect of diazepam on the efficacy of dual-phase FDG-PET imaging. Eur J Nucl Med Mol Imaging 2006;33:228-229 (Pubitemid 43152891)
75. Inoue A, Tomiyama N, Tatsumi M, et al: (18)F-FDG-PET for the evaluation of thymic epithelial tumors: Correlation with the world Health Organization classification in addition to dual-time-point imaging. Eur J Nucl Med Mol Imaging 2009;36:1219-1225
76. Kim SJ, Kim BH, Jeon YK, et al: Limited diagnostic and predictive values of dual-time-point 18F FDG-PET/CT for differentiation of incidentally detected thyroid nodules. Ann Nucl Med 2011;25:347-353
77. Basu S, Chryssikos T, Moghadam-Kia S, et al: Positron emission tomography as a diagnostic tool in infection: Present role and future possibilities. Semin Nucl Med 2009;39:36-51
78. Cook GJ, Fogelman I, Maisey MN: Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation. Semin Nucl Med 1999;26:308-314 (Pubitemid 126789027)
79. Lee ST, Scott AM: Are we ready for dual-time point FDG-PET imaging? J Med Imaging Radiat Oncol 2011;55:351-352 (editorial)
80. Chan WL, Ramsay SC, Szeto ER, et al: Dual-time-point 18F-FDG-PET/CT imaging in the assessment of suspected malignancy. J Med Imaging Radiat Oncol 2011;55:379-390
81. Chen YM, Huang G, Sun XG, et al: Optimizing delayed scan time for FDG-PET: Comparison of the early and late delayed scan. Nucl Med Commun 2008;29:425-430 (Pubitemid 351507535)